When all others said ‘impossible’, Alnylam turned the promise of RNAi into a proven new class of medicines and is at an inflection point to launch a blockbuster medicine. Alnylam has ambitions to address some of the world’s most prevalent diseases. Success is dependent upon fueling the potential of a deep pipeline of clinical and commercial-stage assets. The problem is, How? The answer goes beyond R&D and Commercial capabilities. As Chief of Technical Operational and Quality, Tim Maines has the experience and mindset to scale for the opportunities ahead for siRNA-based medicines and beyond. This session will discuss how to elevate manufacturing innovation as instrumental for helping the most patients.
- Case study: Delivering a new class of medicines and the role of manufacturing, supply chain and quality
- From underappreciated to instrumental – importance of executive leadership for technical, operations and quality capabilities
- Truths in leadership: authentic, nimble, bold, and unafraid
Timothy Maines
Chief Technical Operations & Quality Officer
Alnylam Pharmaceuticals
Tim Maines joined Alnylam in August 2017 as the Global Head of Quality Assurance and Quality Control and was promoted to Chief Technical Operations and Quality Officer in April of 2023, holding over 35 years of experience. Prior to joining Alnylam, Tim was a member of the senior leadership teams at Ariad Pharmaceuticals, Omthera Pharmaceuticals, Astra Zeneca/MedImmune, GTC Biotherapeutics (formerly Genzyme Transgenics) and Stryker Biotech where he provided strategic input and independent quality and technical oversight of each company’s global GxP operations. In total, these experiences resulted with the commercialization and market expansion of thirteen novel medicines, including four FDA-approved therapies at Alnylam.
Tim holds a Bachelor of Science in Biology/Microbiology from Gannon University.
